177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy

被引：1
|
作者：
Clements, Sarah
Tempesta, Daniel
Jacene, Heather
机构：
来源：
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | 2022年 / 50卷 / 03期
关键词：
D O I：
10.2967/jnmt.122.264731
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
[No abstract available]
引用
收藏
页码：213 / 214
页数：2
相关论文
共 50 条
  • [21] Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC A Proof-of-Principle Application
    Bal, Chandrasekhar
    Yadav, Madhav Prasad
    Ballal, Sanjana
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (08) : E386 - E387
  • [22] Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 PSMA-617 Vipivotide Tetraxetan (Pluvicto) on a recently diagnosed prostatic cancer as initial first line therapy.
    Arroyo, Alberto
    Semaan, Hassan
    Dresel, Stefan
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [23] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [24] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [25] Initial Experience with 177Lu-PSMA-617 Therapy: Toxicity and Outcomes PostApproval
    Tuchayi, Abuzar Moradi
    Kim, Sarasa
    Morley, Amanda
    Saelee, Rachelle
    Wang, Yingbing
    Heath, Courtney Lawhn
    Juarez, Roxanna
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [26] Preclinical dosimetric studies of 177Lu-scFvD2B and comparison with 177Lu-PSMA-617 and 177Lu-iPSMA endoradiotherapeutic agents
    Melendez-Alafort, Laura
    Ferro-Flores, Guillermina
    Santos-Cuevas, Clara
    Ocampo-Garcia, Blanca
    Turato, Sofia
    Fracasso, Giulio
    Bolzati, Cristina
    Rosato, Antonio
    De Nardo, Laura
    MEDICAL PHYSICS, 2021, 48 (07) : 4064 - 4074
  • [27] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
    Ngoc, Christina Nguyen
    Happel, Christian
    Davis, Karen
    Groener, Daniel
    Mader, Nicolai
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [28] Production and radiochemical purity of 177Lu-PSMA-617 for clinical trial
    Asad, Ali
    Scharli, Rainer
    Morandeau, Laurence
    Price, Roger
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S527 - S527
  • [29] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [30] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
12345